Stiris Research Inc. awarded Phase Ib trial in Uveal Melanoma

London, ON — November 7, 2017 —

Stiris Research (“Stiris”) an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announces they have entered into a Master Services Agreement (the “MSA”) with an Australian biotechnology company.  Under the terms of the MSA, Stiris is excited to announce that it will commence work with on their Phase Ib open label study in Uveal Melanoma metastatic to liver.

Stiris will work on this new novel investigational virus-based therapy, which has the ability to attack and kill a wide range of cancer cells. This therapy works by attaching to proteins called intracellular adhesion molecule 1 and decay acceleration factor, which are found in excess on the surface of many cancer cells.

“At Stiris, we are passionate about improving the lives of others, and by working with biotechnology companies we have the opportunity to be involved in ground breaking research. We are excited to collaborate with this company on this new novel therapy and look forward to seeing positive outcomes for patients and providing them with greater quality of life,” Amanda Carrera, Vice President.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.